Tune Therapeutics' new method of CRISPR-based gene editing shows promise in curtailing chronic hepatitis B infections.
June 1, 2026 02:48 PM EDT
R&DCell/Gene Tx
Epigenetic editing shows promise against chronic hep B infections
Ryan Cross
Senior Science Correspondent
Tune Therapeutics Presents Positive Phase 1b/2a Proof of Concept Data on TUNE-401: a First-in-Class Epigenetic Silencer for Patients with Hepatitis B at EASL 2026
Experimental Drug May Offer a 'Functional Cure' for Some People with Chronic Hepatitis B
Experimental hepatitis B drug may offer 'functional cure' for some patients
Experimental hepatitis B drug might offer 'functional cure' for a subset of patients
Experimental hepatitis B drug might offer ‘functional cure’ for a subset of patients | CNN
Novel Hep B Drug Delivers Functional Cures in Late-Stage Trials
Experimental hepatitis B drug may offer ‘functional cure’
Hepatitis B drug may offer 'functional cure' for some patients
FDA fast-tracks promising hepatitis B drug after ‘remarkable’ trial results
GSK's chronic hepatitis B drug helps one in five achieve functional cure in key studies
Tune Therapeutics Presents Positive Phase 1b/2a Proof of Concept Data on TUNE-401: a First-in-Class Epigenetic Silencer for…
Across two large trials, roughly 20% of people treated with bepirovirsen had undetectable levels of the virus after stopping all…
Early last year, startup iECURE’s experimental gene therapy seemingly cured a baby of a life-threatening genetic disease. But new…
New research suggests a first-of-its-kind drug for hepatitis B may let some patients stop treatment without showing signs of the…
Gene editing can repair a DNA error in mice that causes Dravet syndrome, a rare, incurable, and potentially deadly form of…
Existing medication only suppresses virus and has to be taken for decades, researcher says.
